White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe-Reference-Cited by-同舟云学术

White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe

Published:2014-10 Issue:19-20 Volume:20 Page:2549-2554
ISSN:1937-3341
Container-title:Tissue Engineering Part A
language:en
Short-container-title:Tissue Engineering Part A

Author:

Erben Reinhold G.¹,Silva-Lima Beatriz²,Reischl Ilona³,Steinhoff Gustav⁴,Tiedemann Gudrun⁴,Dalemans Wilfried⁵,Vos Alexander⁶,Janssen Rob T.A.⁷,Le Blanc Katarina⁸,van Osch Gerjo J.V.M.⁹,Luyten Frank P.¹⁰

Affiliation:

1. Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.

2. iMED.UL, University of Lisbon, Lisbon, Portugal.

3. Austrian Medicines and Medical Devices Agency, BASG/AGES, Vienna, Austria.

4. Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), University of Rostock, Rostock, Germany.

5. TiGenix, Leuven, Belgium.

6. Pharmacell, Maastricht, The Netherlands.

7. Scalable Life Sciences, Zoetermeer, The Netherlands.

8. Division of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden.

9. Department of Orthopaedics and Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

10. Skeletal Biology and Engineering Research Center, and Prometheus, KU Leuven, Leuven, Belgium.

Publisher

Mary Ann Liebert Inc

Subject

Biomedical Engineering,Biomaterials,Biochemistry,Bioengineering

Link

https://www.liebertpub.com/doi/pdf/10.1089/ten.tea.2013.0589

Reference9 articles.

1. Regulatory Frameworks for Cell and Tissue Based Therapies in Europe and the USA

2. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine

3. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells

4. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice

5. Marker tolerant, immunocompetent animals as a new tool for regenerative medicine and long-term cell tracking

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing biodistribution of biomedical cellular product based on human chondrocytes following implantation to BALB/C nude mice;Medicine of Extreme Situations;2023-12

2. Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells;Stem Cell Research & Therapy;2022-05-26

3. Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia;International Journal of Molecular Sciences;2020-11-09

4. Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries;Regenerative Medicine;2020-08

5. Regenerative medicine regulatory policies: A systematic review and international comparison;Health Policy;2020-07